(Q36746794)
Statements
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer (English)
D W Miles
S L de Haas
L Y Dirix
G Romieu
A Chan
P Tomczak
L Provencher
P R Delmar
S J Scherer
19 February 2013
1 reference
1 reference
1 reference